Evidence map›Paper›PMID 39461880›Full record

ArticleJournal for immunotherapy of cancer2024

Sara K Silbert, Samantha Scanlon, Hao-Wei Wang, Constance M Yuan, Alyssa Doverte, Jake Wellek, Nisha Patel, Raul Braylan, Mark Ahlman, Evrim B Turkbey and 12 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sara K Silbert *National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USA.
Samantha Scanlon *Department of Pediatric Hematology & Oncology, University of Washington, Seattle, Washington, USA.
Hao-Wei WangLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Constance M YuanLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Alyssa DoverteLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Jake WellekLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Nisha PatelHematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Raul BraylanHematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Mark AhlmanDepartment of Radiology and Imaging, Medical College of Georgia, Augusta, Georgia, USA.
Evrim B TurkbeyRadiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Sandra D BohlingDepartment of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
Karen M ChisholmDepartment of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
Murat Alp OztekDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Mike LaLoggiaLake Erie College of Osteopathic Medicine, Rochester, New York, USA.
Anupam VermaNational Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USA.
Haneen ShalabiNational Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USA.
Alexandra E KovachHematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Brent L WoodHematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Adam LambleDepartment of Pediatric Hematology & Oncology, University of Washington, Seattle, Washington, USA.
Ilan KirschAdaptive Biotechnologies, Seattle, Washington, USA.
Kasey Leger *Department of Pediatric Hematology & Oncology, University of Washington, Seattle, Washington, USA nirali.shah@nih.gov Kasey.Leger@seattlechildrens.org.
Nirali N Shah *National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USA nirali.shah@nih.gov Kasey.Leger@seattlechildrens.org.ORCID 0000-0002-8474-9080

Funding

Immunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1M
Intramural NIH HHS ZIA BC011823
6 · The paper itself

Abstract

Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with

Indexed as

Antigens, CD19Leukemia, Myeloid, AcuteReceptors, CytokineAdolescentCell LineageFemaleGene RearrangementHumansMaleMolecular Targeted TherapyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntigens, CD19CD19 molecule, humanCRLF2 protein, humanReceptors, CytokineChimeric antigen receptor - CARImmunotherapyLeukemiaNext generation sequencing - NGS

Identifiers

PMID39461880
PMCPMC11529463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.